Delcath Systems, Inc.
Index- P/E- EPS (ttm)-3.80 Insider Own1.80% Shs Outstand8.32M Perf Week-2.14%
Market Cap34.32M Forward P/E- EPS next Y-2.12 Insider Trans222.44% Shs Float6.77M Perf Month-5.82%
Income-30.30M PEG- EPS next Q-0.98 Inst Own19.70% Short Float3.14% Perf Quarter0.12%
Sales3.80M P/S9.03 EPS this Y57.00% Inst Trans1.17% Short Ratio9.36 Perf Half Y-26.86%
Book/sh-0.35 P/B- EPS next Y32.60% ROA-104.70% Target Price18.60 Perf Year-60.26%
Cash/sh1.23 P/C3.36 EPS next 5Y15.00% ROE-465.60% 52W Range3.49 - 11.95 Perf YTD-46.77%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-63.77% Beta0.90
Dividend %- Quick Ratio1.40 Sales past 5Y12.30% Gross Margin85.00% 52W Low24.07% ATR0.21
Employees45 Current Ratio1.60 Sales Q/Q60.00% Oper. Margin- RSI (14)52.47 Volatility4.58% 4.96%
OptionableYes Debt/Eq- EPS Q/Q-22.50% Profit Margin- Rel Volume1.11 Prev Close4.12
ShortableYes LT Debt/Eq- EarningsAug 08 BMO Payout- Avg Volume22.73K Price4.33
Recom1.60 SMA20-0.01% SMA503.41% SMA200-26.41% Volume4,104 Change4.97%
Jul-26-22Resumed Canaccord Genuity Buy $17
Dec-10-21Initiated H.C. Wainwright Buy $25
Mar-09-21Initiated Canaccord Genuity Buy $24
Jan-05-21Initiated BTIG Research Buy $23
Jun-01-20Initiated Laidlaw Buy $19
Sep-01-22 04:15PM  
Aug-08-22 07:45AM  
Aug-05-22 08:30AM  
Jul-27-22 04:30PM  
Jul-20-22 04:10PM  
Jul-18-22 08:30AM  
Jun-07-22 07:06AM  
Jun-06-22 04:15PM  
May-10-22 07:30AM  
May-09-22 08:30AM  
May-02-22 03:02PM  
Apr-28-22 09:00AM  
Apr-08-22 09:00AM  
Mar-29-22 09:00AM  
Mar-25-22 07:30AM  
Mar-15-22 04:30PM  
Mar-10-22 09:00AM  
Mar-02-22 04:01PM  
Feb-22-22 09:00AM  
Feb-10-22 04:30PM  
Feb-07-22 04:01PM  
Feb-04-22 09:00AM  
Feb-03-22 04:30PM  
Jan-25-22 04:01PM  
Jan-07-22 09:00AM  
Dec-02-21 08:00AM  
Nov-30-21 08:30AM  
Nov-11-21 06:06AM  
Nov-09-21 07:30AM  
Nov-08-21 12:49PM  
Nov-05-21 09:00AM  
Nov-02-21 03:02PM  
Oct-25-21 04:01PM  
Sep-02-21 09:00AM  
Aug-10-21 07:30AM  
Aug-09-21 07:30AM  
Aug-05-21 09:00AM  
Aug-03-21 03:00PM  
Jul-28-21 09:00AM  
Jul-08-21 11:20AM  
Jul-07-21 09:00AM  
Jun-23-21 09:35AM  
Jun-08-21 09:00AM  
Jun-07-21 12:21PM  
Jun-03-21 09:00AM  
May-26-21 09:00AM  
May-24-21 06:17AM  
May-11-21 08:00AM  
May-03-21 02:33AM  
Apr-30-21 04:01PM  
Apr-21-21 08:38AM  
Mar-31-21 02:55PM  
Mar-24-21 04:01PM  
Mar-08-21 09:00AM  
Feb-11-21 09:00AM  
Jan-11-21 10:56AM  
Dec-11-20 10:31AM  
Dec-09-20 08:00AM  
Dec-08-20 04:01PM  
Dec-07-20 07:30AM  
Nov-11-20 08:00AM  
Nov-02-20 04:01PM  
Oct-29-20 07:30AM  
Oct-01-20 04:07PM  
Sep-28-20 10:50AM  
Sep-10-20 09:00AM  
Sep-02-20 05:36PM  
Aug-25-20 04:01PM  
Aug-13-20 04:01PM  
Aug-06-20 04:01PM  
Aug-05-20 09:00AM  
Aug-03-20 01:48PM  
May-26-20 08:30AM  
May-19-20 08:30AM  
May-15-20 06:30AM  
May-05-20 04:05PM  
May-01-20 10:17AM  
Feb-19-20 08:30AM  
Jan-13-20 08:30AM  
Dec-19-19 08:30AM  
Dec-03-19 08:30AM  
Oct-22-19 07:27AM  
Oct-18-19 08:00AM  
Oct-15-19 08:00AM  
Oct-08-19 08:00AM  
Sep-23-19 11:30AM  
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MICHEL GERARD JChief Executive OfficerJul 20Buy3.9862,814250,000125,864Jul 21 10:29 AM
Purpura JohnChief Operating OfficerMay 16Buy4.613,30015,21327,021May 18 10:42 AM
SALAMON STEVEN A JDirectorMay 13Buy5.035,00025,135440,100May 16 12:04 PM
SALAMON STEVEN A JDirectorMay 12Buy4.906,00029,42429,424May 13 12:12 PM
SALAMON STEVEN A JDirectorApr 19Buy6.251,60010,000429,100Apr 20 03:47 PM
Rosalind Advisors, Inc.DirectorApr 19Buy6.251,60010,000433,100Apr 21 12:42 PM
Rosalind Advisors, Inc.DirectorApr 18Buy6.352,00012,697431,500Apr 19 01:52 PM
Aharon GilDirectorApr 18Buy6.352,00012,697404,000Apr 19 01:52 PM
MICHEL GERARD JSee RemarksApr 18Buy6.372,00012,73463,050Apr 18 09:23 PM
SALAMON STEVEN A JDirectorApr 13Buy6.451,5009,675427,500Apr 14 01:47 PM
Rosalind Advisors, Inc.DirectorApr 13Buy6.451,5009,675429,500Apr 14 05:20 PM
Rosalind Advisors, Inc.DirectorApr 12Buy6.482,50016,200428,000Apr 12 06:42 PM
SALAMON STEVEN A JDirectorApr 12Buy6.482,50016,200425,000Apr 12 05:58 PM
Purpura JohnChief Operating OfficerApr 11Buy6.595,00032,95023,721Apr 11 04:11 PM
MICHEL GERARD JSee RemarksApr 08Buy6.572,00013,13661,050Apr 08 06:25 PM
Rosalind Advisors, Inc.DirectorApr 07Buy6.411,0006,410425,500Apr 08 09:43 AM
Rosalind Advisors, Inc.DirectorApr 06Buy6.491,0006,490424,500Apr 08 09:43 AM
SALAMON STEVEN A JDirectorDec 30Buy7.562,00015,120421,500Jan 03 02:04 PM
Rosalind Advisors, Inc.DirectorDec 30Buy7.562,00015,120423,500Jan 03 02:02 PM
MICHEL GERARD JSee RemarksDec 02Buy8.6123,200199,75259,050Dec 06 06:06 PM